REG-PanGenomic Health Inc: AGM Results

Pangenomic HealthAnnouncement

02/05/2023 08:45

2 May 2023

PanGenomic Health Inc.

(“PanGenomic” or the “Company”)

PanGenomic Health Announces AGM Results

Vancouver, British Columbia, Canada, May 2, 2023 – PanGenomic Health Inc.
("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to
announce the results of its Annual General Meeting held on April 26, 2023 (the
“Meeting”).

All Company matters submitted to shareholders for approval as set out in the
Company's Notice of Meeting and Management Information Circular, dated March
21, 2023 (the “Information Circular”), were approved by the requisite
majority of votes cast at the meeting.  A copy of the Company’s Information
Circular is available under the Company’s profile at www.sedar.com.

In addition to the presentation of the Company’s audited financial
statements for the year ended December 31, 2021 and the Company’s annual
benefit report for the years ended December 31, 2022 and December 31, 2021, at
the Meeting (i) the number of directors for the upcoming year was set at five
(5) directors; (ii) each nominee director set forth in the Information
Circular was elected to the Company’s board; (iii) Saturna Group Chartered
Professional Accountants LLP were reappointed as auditors for the Company; and
(iv) the Company’s rolling 20% stock option plan was ratified and confirmed.

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care
digital platform to deliver personalised, evidence-based information about
natural treatments. The Company’s initial focus is to support mental health.
Registered as a British Columbia benefit company, PanGenomic Health's mission
is to promote and improve the health and wellness of people and society by
providing a technology platform that identifies plant-based solutions tailored
to the health profile of each individual.

The Directors of PanGenomic take responsibility for this announcement.

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

For more information, please contact:

Jerry Lai, Investor
Relations                                      
Maryam Marissen, President & CEO

PanGenomic Health
Inc.                                           
PanGenomic Health Inc.

778 743
4642                                                             
778 743 4642

ir@pangenomic.com                                                 
info@pangenomic.com

Novum Securities Limited, AQSE corporate Advisor

David Coffman / George Duxberry

Tel: +44 (0)207 399 9400

Yellow Jersey PR
Charles Goodwin / Shiv Thambirajah / Soraya Jackson
Investor Relations, UK
Tel: +44 (0)20 3004 9512

This news release includes certain statements that may be deemed
“forward-looking statements”, including statements respecting the services
to be provided by PanGenomic and the consideration to be paid to PanGenomic.
The use of any of the words “anticipate”, “continue”, “estimate”,
“expect”, “may”, “will”, “would”, “project”, “should”,
“believe” and similar expressions are intended to identify forward looking
statements. Although PanGenomic believes that the expectations and assumptions
on which the forward-looking statements are based are reasonable, undue
reliance should not be placed on the forward-looking statements because
PanGenomic can give no assurance that they will prove to be correct. In
particular, there is no assurance that MUJN Diagnostics and/or Psy Integrated
will be able to complete trial biomarker testing program within the timeframes
expected, or at all. Since forward-looking statements address future events
and conditions, by their very nature they involve inherent risks and
uncertainties. These statements speak only as of the date of this News
Release. Actual results could differ materially from those currently
anticipated due to a number of factors and risks including various risk
factors discussed in PanGenomic’s disclosure documents which can be found
under PanGenomic’s profile on www.sedar.com.



Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved